Physician profile
John Kalliel
NPI 1710059209
$13,597.14
in general payments reported to CMS, 2019-2025
33 companies · $2,145 in 2025
The $2,145 reported for 2025 was more than what 94% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,629 · 2020: $1,684 · 2021: $1,943 · 2022: $2,179 · 2023: $2,221 · 2024: $1,796 · 2025: $2,145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,137 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,137.33 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,293.96 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Regeneron Healthcare Solutions, INC. | $1,982.30 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $1,593.39 | 2019-2025 | Nucala, Trelegy Ellipta, Shingrix |
| Csl Behring | $1,003.70 | 2019-2025 | Haegarda, Hizentra, Andembry |
| Takeda Pharmaceuticals U.S.A., INC. | $961.42 | 2020-2025 | Cuvitru, Takhzyro, Eohilia |
| Novartis Pharmaceuticals Corporation | $816.84 | 2019-2025 | |
| Pfizer INC. | $785.78 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $550.44 | 2019-2021 | |
| Pharming Healthcare, INC. | $523.96 | 2019-2025 | Ruconest |
| Genzyme Corporation | $510.76 | 2019-2025 | |
| Grifols USA, LLC | $402.37 | 2019-2024 | Xembify |
| Kaleo, INC. | $387.14 | 2019-2024 | Auvi-Q |
| Biocryst US Sales Co., LLC | $377.50 | 2021-2025 | Orladeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $233.52 | 2019-2023 | Spiriva Respimat |
| Amgen INC. | $219.51 | 2022-2025 | Tezspire |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $184.45 | 2020-2022 | |
| Genentech USA, INC. | $103.09 | 2022-2025 | Xolair |
| Ionis Pharmaceuticals, INC. | $90.23 | 2025 | Dawnzera |
| Biocryst Pharmaceuticals, INC. | $72.68 | 2020 | |
| Optinose US, INC. | $68.58 | 2019-2020 | |
| Gc Biopharma USA, INC. | $66.23 | 2025 | Alyglo |
| Merck Sharp & Dohme LLC | $62.17 | 2019-2021 | |
| Shire North American Group INC | $61.09 | 2019 | |
| Abbvie INC. | $59.40 | 2022-2023 | |
| Ars Pharmaceuticals Operations, INC. | $37.89 | 2025 | Neffy |
| Circassia INC. | $29.90 | 2019 | |
| Cycle Pharmaceuticals INC | $22.38 | 2025 | Sajazir |
| Lilly USA, LLC | $20.97 | 2024 | Taltz, Ebglyss |
| Eyevance Pharmaceuticals LLC | $19.43 | 2021 | |
| Bio Products Laboratory USA, INC. | $15.84 | 2019 | |
| Greer Laboratories, INC. | $14.67 | 2019 | |
| Sanofi Pasteur INC. | $13.76 | 2019 | |
| Incyte Corporation | $11.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Kalliel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.